ESR1 and ovarian cancer: A recent study showed the potential of miR-214 to overcome the resistance to tamoxifen and fulvestrant in estrogen receptor-positive breast cancer cells44, and miR-214 was reported to induce the resistance to cisplatin in human ovarian cancer cells via the PTEN/Akt pathway29.